Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma

NEJM

Ibrutinib treatment in combination with standard chemoimmunotherapy significantly prolonged progression-free survival. The safety profile of the combined therapy was consistent with the known profiles of the individual drugs.